Montuschi, Paolo
 Distribuzione geografica
Continente #
NA - Nord America 3.484
AS - Asia 2.769
EU - Europa 2.709
SA - Sud America 684
AF - Africa 75
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 6
Totale 9.741
Nazione #
US - Stati Uniti d'America 3.385
SG - Singapore 1.331
CN - Cina 718
DE - Germania 608
SE - Svezia 566
BR - Brasile 551
IT - Italia 354
UA - Ucraina 267
IE - Irlanda 177
VN - Vietnam 145
GB - Regno Unito 140
FR - Francia 120
ID - Indonesia 115
PL - Polonia 112
FI - Finlandia 94
IN - India 94
TR - Turchia 71
RU - Federazione Russa 69
HK - Hong Kong 64
CA - Canada 47
AR - Argentina 45
BD - Bangladesh 41
NL - Olanda 35
AT - Austria 33
BE - Belgio 32
MX - Messico 31
ZA - Sudafrica 29
IQ - Iraq 25
JP - Giappone 25
EC - Ecuador 22
ES - Italia 20
KR - Corea 20
CL - Cile 16
PK - Pakistan 16
IR - Iran 15
CO - Colombia 14
CH - Svizzera 13
MA - Marocco 13
SA - Arabia Saudita 13
AU - Australia 12
IL - Israele 10
VE - Venezuela 10
LT - Lituania 9
AZ - Azerbaigian 8
EG - Egitto 8
PY - Paraguay 8
UZ - Uzbekistan 8
BG - Bulgaria 7
CZ - Repubblica Ceca 7
UY - Uruguay 7
AL - Albania 6
KE - Kenya 6
PT - Portogallo 6
AE - Emirati Arabi Uniti 5
JO - Giordania 5
PE - Perù 5
PH - Filippine 5
EU - Europa 4
KZ - Kazakistan 4
MY - Malesia 4
NP - Nepal 4
OM - Oman 4
PA - Panama 4
RS - Serbia 4
TN - Tunisia 4
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
HN - Honduras 3
HR - Croazia 3
IS - Islanda 3
KG - Kirghizistan 3
LU - Lussemburgo 3
LV - Lettonia 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AO - Angola 2
CR - Costa Rica 2
DK - Danimarca 2
EE - Estonia 2
GE - Georgia 2
GR - Grecia 2
IM - Isola di Man 2
KH - Cambogia 2
LB - Libano 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
YE - Yemen 2
BB - Barbados 1
BF - Burkina Faso 1
BH - Bahrain 1
BZ - Belize 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
ET - Etiopia 1
GA - Gabon 1
GF - Guiana Francese 1
Totale 9.723
Città #
Singapore 584
Chandler 491
Ashburn 387
Dublin 172
Beijing 148
San Mateo 147
Jacksonville 120
Cattolica 114
Nanjing 110
Warsaw 108
Jakarta 102
Ann Arbor 101
New York 99
Los Angeles 89
Bremen 87
Wilmington 84
Boston 76
Woodbridge 74
Munich 66
Fairfield 59
Lawrence 55
Redwood City 55
Hefei 54
Ho Chi Minh City 54
Hong Kong 52
Moscow 51
Izmir 46
Dearborn 43
Seattle 43
The Dalles 43
São Paulo 42
Dallas 41
Milan 40
Buffalo 39
Houston 39
Rome 39
Frankfurt am Main 37
Hanoi 33
Princeton 33
Boardman 29
Brussels 29
Hangzhou 26
Shanghai 23
Vienna 23
Rio de Janeiro 22
Guangzhou 21
Nanchang 21
Chicago 20
Kent 20
Nürnberg 20
Cambridge 19
Marseille 19
Norwalk 19
Santa Clara 19
Columbus 18
Mountain View 18
Montreal 17
Redmond 17
Tokyo 17
Johannesburg 16
Helsinki 15
London 15
Shenyang 15
Dhaka 14
Fremont 14
Hebei 14
Brooklyn 13
Nuremberg 13
Pune 13
Seoul 13
Stockholm 13
Tianjin 13
Amsterdam 11
Falls Church 11
Jiaxing 11
Lancaster 11
Toronto 11
Zhengzhou 11
Changsha 10
Detroit 10
Düsseldorf 10
Orem 10
Porto Alegre 10
San Francisco 10
Turku 10
University Park 10
Baghdad 9
Belo Horizonte 9
Buenos Aires 9
Lappeenranta 9
Mexico City 9
Miami 9
Salvador 9
Baku 8
Changchun 8
Istanbul 8
Mumbai 8
Paris 8
Quito 8
Atlanta 7
Totale 4.919
Nome #
Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD 304
Development of a sensing array for human breath analysis based on SWCNT layers functionalized with semiconductor organic molecules 226
Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers 210
Computed tomography for evaluation of the small airway disease in asthma. 202
Detection and characterization of extracellular vesicles in exhaled breath condensate and sputum of COPD and severe asthma patients 177
Impact of air pollution on respiratory diseases in urban areas: a systematic review 167
Electronic Nose and Exhaled Breath NMR-based Metabolomics Applications in Airways Disease 165
Within-day and between-day repeatability of measurements with an electronic nose in patients with COPD 162
Electronic Nose and Exhaled Breath NMR-based Metabolomics Applications in Airways Disease 162
Electronic nose and exhaled breath NMR-based metabolomics applications in airways disease 155
Liquid chromatography-mass spectrometry measurement of leukotrienes in asthma and other respiratory diseases 153
Metabolomic analysis of exhaled breath condensate in patients with asthma and COPD 149
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 149
Inhaled muscarinic acethylcholine receptor antagonists for treatment of COPD 147
Development of a Sensing Array for Human Breath Analysis Based on SWCNT Layers Functionalized with Semiconductor Organic Molecules 144
Electronic nose and exhaled breath NMR-based metabolomics applications in airways disease 143
Investigational prostaglandin D2 receptor antagonists for airway inflammation 141
Dupilumab for the treatment of asthma 134
U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics 132
Exploring the performance of a functionalized CNT-based sensor array for breathomics through clustering and classification algorithms: From gas sensing of selective biomarkers to discrimination of chronic obstructive pulmonary disease 131
NMR spectroscopy-based metabolomics of exhaled breath condensate in inflammatory respiratory diseases 123
Exhaled Nitric Oxide Measurement in Patients Affected by Nasal Polyposis 121
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry 119
Pharmacotherapy of asthma: regular treatment or on demand? 116
Leukotriene modifiers for asthma treatment 112
Gallbladder emptying, plasma levels of estradiol and progesterone, and cholecystokinin secretion in liver cirrhosis 112
Indirect monitoring of lung inflammation 111
Liquid chromatography/mass spectrometry analysis of exhaled leukotriene B4 in asthmatic children 111
NMR-Based Metabolomics for the Assessment of Inhaled Pharmacotherapy in Chronic Obstructive Pulmonary Disease Patients 110
Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers 107
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 107
Impulse oscillometry and nitrogen washout test in the assessment of small airway dysfunction in asthma: correlation with quantitative computed tomography 106
Novel perspectives in the detection of oral and nasal oxidative stress and inflammation in pediatric united airway diseases 105
Stratification of asthma phenotypes by airway proteomic signatures 105
Severe asthma: One disease and multiple definitions 105
Comparison of classification methods in breath analysis by electronic nose 104
Dupilumab for the treatment of asthma 102
8-isoprostane in exhaled breath condensate after experimental exposure to wood smoke in humans 100
Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends 97
LC/MS/MS analysis of leukotriene B4 in exhaled breath condensate for assessing lung inflammation. 96
The combined impact of exhaled nitric oxide and sputum eosinophils monitoring in asthma treatment: a prospective cohort study 95
Medication Adherence in Patients With Severe Asthma Prescribed Oral Corticosteroids in the U-BIOPRED Cohort 92
Non-invasive biomarkers of lung inflammation in smoking subjects 92
Role of beta-blockers in patients with COPD: current perspective 92
Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort 91
IL-17-high asthma with features of a psoriasis immunophenotype 90
8-Isoprostane in exhaled breath condensate and exercise-induced bronchoconstriction in asthmatic children and adolescents. 89
Immediate allergic reactions to beta-lactams: diagnosis and therapy. 87
Comparison of two exhaled biomarkers in children with and without sleep disordered breathing 87
Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers 87
Exhaled breath condensate in COPD: application in clinical practice 86
WHITIN-DAY AND BETWEEN-DAY REPEATIBILITY OF MEASURERMENTS WITH AN ELECTRONIC NOSE IN PATIENTS WITH COPD 85
Pharmacotherapy of patients with mild persistent asthma: strategies and unresolved issues 83
Application of 'omics technologies to biomarker discovery in inflammatory lung diseases. 83
The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease 83
New perspectives in pharmacological treatment of mild persistent asthma 82
Long-acting beta-agonists and their association with inhaled corticosteroids in COPD 80
Drugs for chronic obstructive pulmonary disease. 79
The electronic nose in respiratory medicine. 78
Triple inhaled therapy for chronic obstructive pulmonary disease 78
Exhaled volatile organic compounds as markers for medication use in asthma 77
Within-day and between-day repeatability of measurements with an electronic nose in patients with COPD 76
Treatable traits in the European U-BIOPRED adult asthma cohorts 76
Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects 76
Predictive markers of bronchial hyperreactivity in a large cohort of young adults With cough variant asthma 76
NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis 75
Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma 75
eNose breath prints as a surrogate biomarker for classifying patients with asthma by atopy 74
Diagnostic performance of an electronic nose, fractional exhaled nitric oxide, and lung function testing in asthma. 74
Separating Smoking-Related Diseases Using NMR-Based Metabolomics of Exhaled Breath Condensate 74
Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis 73
Lipid phenotyping of lung epithelial lining fluid in healthy human volunteers 73
Exhaled breath condensate biomarkers of airway inflammation and oxidative stress in COPD 72
Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping 72
Exhaled nitric oxide as a biomarker in COPD and related comorbidities 72
Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study 71
Nuclear magnetic resonance-based metabolomics of exhaled breath condensate: methodological aspects 71
Sputum proteomic signature of gastro-oesophageal reflux in patients with severe asthma 71
Nuclear magnetic resonance-based metabolomics discriminates primary ciliary dyskinesia from cystic fibrosis 69
The potential role of endothelial dysfunction and platelet activation in the development of thrombotic risk in COPD patients 68
Methodological considerations for large-scale breath analysis studies: lessons from the U-BIOPRED severe asthma project 67
Editorial: Insights in respiratory pharmacology: 2021 63
Exhaled breath condensate, nasal eosinophil cationic protein level and nasal cytology during immunotherapy for cypress allergy. 63
Characteristics and treatment regimens across ERS SHARP severe asthma registries 63
High sputum total adiponectin is associated with low odds for asthma. 62
Urinary Leukotriene E4 and Prostaglandin D2 Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study 61
Exhaled 8-isoprostane and prostaglandin E2 in patients with stable and unstable cystic fibrosis. 58
Epithelial dysregulation in obese severe asthmatics with gastro-oesophageal reflux 57
Mapping atopic dermatitis and anti-IL-22 response signatures to type 2-low severe neutrophilic asthma 57
Transcriptional regulation of kinases downstream of the T cell receptor: another immunomodulatory mechanism of glucocorticoids 56
The role of inflammation in anxiety and depression in the European U-BIOPRED asthma cohorts 55
Vilanterol trifenatate for the treatment of COPD 55
Role of beta-blockers in patients with COPD: current perspective 52
Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort 51
Large-Scale Label-Free Quantitative Mapping of the Sputum Proteome 50
Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis 49
Haemophilus influenzae and Moraxella catarrhalis in sputum of severe asthma with inflammasome and neutrophil activation 41
Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation 39
A European Respiratory Society technical standard: exhaled biomarkers in lung disease 39
Asthma similarities across ProAR (Brazil) and U-BIOPRED (Europe) adult cohorts of contrasting locations, ethnicity and socioeconomic status 38
Totale 9.782
Categoria #
all - tutte 46.596
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.596


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021382 0 0 0 0 0 24 57 16 102 49 117 17
2021/2022868 57 64 22 68 66 35 22 138 39 46 173 138
2022/20231.633 201 215 131 277 133 226 48 125 186 17 45 29
2023/2024815 34 248 17 113 26 104 56 10 7 39 64 97
2024/20251.555 32 50 124 54 121 39 57 54 237 159 352 276
2025/20262.519 713 167 267 456 797 119 0 0 0 0 0 0
Totale 9.885